Drug Type Monoclonal antibody |
Synonyms REGN 4461, REGN4461 |
Target |
Mechanism LEPR agonists(Leptin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity | Phase 2 | US | 24 Apr 2024 | |
Obesity | Phase 2 | MX | 24 Apr 2024 | |
Lipodystrophy, Familial Partial | Phase 2 | US | 28 Feb 2022 | |
Lipodystrophy, Familial Partial | Phase 2 | FR | 28 Feb 2022 | |
Lipodystrophy, Familial Partial | Phase 2 | ES | 28 Feb 2022 | |
Lipodystrophy, Familial Partial | Phase 2 | TR | 28 Feb 2022 | |
Lipodystrophy, Congenital Generalized | Phase 2 | US | 07 Jan 2020 | |
Lipodystrophy, Congenital Generalized | Phase 2 | PE | 07 Jan 2020 | |
Lipodystrophy, Congenital Generalized | Phase 2 | RU | 07 Jan 2020 | |
Lipodystrophy, Congenital Generalized | Phase 2 | TR | 07 Jan 2020 |